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A B S T R A C T
Response to polysaccharide vaccination can be an invaluable tool for assessing functionality of the adaptive
immune system. Measurement of antibodies raised in response to Pneumovax®23 is the current gold standard
test, but there are signiﬁcant challenges and constraints in both the measurement and interpretation of the
response. An alternative polysaccharide vaccine approach (Salmonella typhi Vi capsule (ViCPS)) has been sug-
gested. In the present article, we review current evidence for the measurement of ViCPS antibodies in the
diagnosis of primary and secondary antibody deﬁciencies. In particular, we review emerging data suggesting
their interpretation in combination with the response to Pneumovax®23 and comment upon the utility of these
vaccines to assess humoral immune responses while receiving immunoglobulin replacement therapy (IGRT).
1. Introduction
Primary immunodeﬁciencies (PIDs) are a group of over 300 diseases
caused by inherited or genetic defects in one or more components of the
immune system (Picard et al., 2015). Timely and appropriate diagnosis
of PID is imperative to optimise patient treatment, reduce the risk of
infections, comorbidities and avoid permanent tissue or organ damage
(Chapel et al., 2014; Sanges et al., 2017; Yazdani et al., 2017). More-
over, patient healthcare costs have been demonstrated to be sub-
stantially reduced after a diagnosis of PID (Modell et al., 2011). Sec-
ondary immunodeﬁciencies (SID) originate from external underlying
factors that are not primary in origin but compromise the function of
the immune system. Causes that may suppress the immune system in-
clude haematological malignancies, immunosuppressive drugs for ex-
ample B cell ablation therapies like rituximab and pathogens such as
the human immunodeﬁciency virus (HIV; reviewed in Dhalla and
Misbah (2015))(Sánchez–Ramón et al., 2016).
Impairment of speciﬁc antibody responses is characteristic of a
number of humoral immunodeﬁciencies, rendering individuals sus-
ceptible to recurrent and severe infections with encapsulated bacteria
as well as rare opportunistic pathogens (McCusker and Warrington,
2011; de Vries, 2012; Sanges et al., 2017). The measurement of re-
sponses to T-cell dependent and T-cell independent antigens is essential
for evaluation of the adaptive immune system (de Vries, 2008) and is
recommended in peer-reviewed guidelines to aid in the clinical re-
cognition and diagnosis of antibody deﬁciencies (de Vries, 2012;
Orange et al., 2012; Bonilla et al., 2015). There are several primary
antibody disorders in which assessment particularly rests on the de-
termination of vaccine responses: transient hypogammaglobulinaemia
of infancy (THI), IgG subclass 1, 2 and 3 deﬁciency, IgA deﬁciency
(IgAD) and speciﬁc polysaccharide antibody deﬁciency (SPAD). The
growing category of undeﬁned hypogammaglobulinaemia also requires
careful assessment of vaccine responses. Likewise, utilising the anti-
body response to speciﬁc antigens has also been recommended in the
diagnostic assessment and subsequent monitoring of IGRT in im-
munodeﬁcient patients (Jolles et al., 2017).
The clinical measurement of T-cell independent immunity can be
achieved by measuring the antibody response to several polysaccharide
antigens such as isohaemagglutinins, meningococcal and pneumococcal
polysaccharide vaccines (Menactra® and Pneumovax®23, respectively),
as well as alternative vaccines such as Salmonella typhi Vi poly-
saccharide (Typhim Vi®). At present, the gold standard for assessment
of T-cell independent responses is to determine the IgG response to
Pneumovax®23, which contains extracts of 23 pneumococcal capsular
serotypes. Pneumovax®23 provides protection against 80–90% of
pneumococcal serotypes that cause invasive pneumococcal disease and
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is recommended in all adults 65 years of age and older, as well as in
individuals at-risk of infection who are> 2 years of age (Centers for
Disease Control and Prevention, 2010; Daniels et al., 2016; Public
Health England, 2017).
There have been a number of reports highlighting the utility of the
antibody response to Pneumovax®23 in assessment of immune system
functionality, however, despite being the most commonly used test and
employed in many laboratories (Edgar et al., 2018), both measurement
and interpretation remains challenging. Furthermore, widespread vac-
cination of children using conjugated pneumococcal vaccines, such as
Prevenar 13™, adds to the complexity of result interpretation (sum-
marised in Table 1). These factors have spurred the search for alter-
native polysaccharide antigens to assess T-cell independent humoral
responses and consequently measurement of the antibodies raised in
response to Typhim Vi® has gathered momentum in recent years. The
focus of this review is to discuss the evidence in support of ViCPS an-
tibody assessment as an additional tool to identify individuals with poor
T-cell independent adaptive immunity.
2. Vi capsular polysaccharide (ViCPS) vaccines
ViCPS is a linear homopolymer of poly-alpha(1→ 4)GalNAcp whose
immunogenicity, in the organism Salmonella typhi, may depend on post
translation modiﬁcations (Szu et al., 1991). Puriﬁed Vi antigen is a
potent immunogen (Ahmadi et al., 2013) and hence a prime target for
vaccine development against typhoid fever. Two main types of typhoid
vaccines are currently available; ViCPS vaccines and a live-attenuated
oral vaccine that contains the Salmonella typhi strain (Ty21a). Ad-
ditionally, there is a limited availability of Vi-polysaccharide-protein
conjugate (Vi-conjugate) vaccines, which are currently licensed for use
in China and India only (Schadich et al., 2016) (Table 2).
ViCPS vaccines are licensed for use in adults and children over
2 years old and are used in areas where typhoid fever is endemic, as
well as for travellers to those areas (Table 2, (Schadich et al., 2016)).
ViCPS vaccines have been shown to be eﬀective in preventing
Salmonella typhi Vi infection (Acharya et al., 1987; Klugman et al.,
1987; Dizer et al., 2002), a recent Japanese study reported ser-
oconversion 28 days post-vaccination occurring in> 90% of in-
dividuals (Miyazu et al., 2015). Vaccination with ViCPS vaccines in-
duces a predominantly IgG2 antibody response (Jin et al., 2017) but
does not induce long term immunological memory as it provokes a T-
cell independent response (Keitel et al., 1994). It is therefore re-
commended that at risk individuals receive revaccination every two
years (Froeschle and Decker, 2010).
2.1. B cells analysis and Typhi Vi IgG production
The antibody response to ViCPS vaccination generates antigen-
speciﬁc plasmablasts (Kantele et al., 1986; Kantele, 1990; Kantele and
Makela, 1991; Sundstrom et al., 2008; Lundgren et al., 2009; Pakkanen
et al., 2010) which aids distribution and localisation of the humoral
response to eﬀector sites using tissue speciﬁc homing receptors (Kantele
et al., 2013). Post Typhim Vi® vaccination, the homing proﬁle of ViCPS
induced plasmablasts consisted of the following homing receptors: 84%
peripheral lymph node, L-selectin, 56% intestinal, α4β7-integrin, and
4% cutaneous, cutaneous lymphocyte antigen (CLA). Ty21a plasma-
blasts had a diﬀerent homing proﬁle. Capsular polysaccharides are re-
garded as T cell independent Type II antigens and in mice the antibody
response to the Vi antigen is governed by B1b cells (Marshall et al.,
2012). In humans, the ViCPS antibody response involves splenic mar-
ginal zone B cells (Guinamard et al., 2000; Martin et al., 2001; Martin
and Kearney, 2002; Weill et al., 2009) and a B1b analogue has been
proposed in human common variable immunodeﬁciency (CVID) pa-
tients (Rakhmanov et al., 2009; Griﬃn et al., 2011). Two recent studies
have investigated the presence of B cell populations in response to
Typhim Vi® vaccination; Bausch-Jurken et al. report IgG responders to
Typhim Vi® vaccination have a higher percentage of both B cells and
switched memory B cells (Bausch-Jurken et al., 2017) and Evans et al.
report the total number of B cells, but not percentage of B cells, to be
higher in IgG responders than non-responders (Evans et al., 2018).
Table 1
Challenges in the interpretation of response to Pneumovax®23 and comparison with the use of ViCPS.
Challenges in the interpretation of response to Pneumovax®23 Solutions provided by measurement of response to ViCPS vaccines
Lack of consensus analytical approach to measure response to Pneumovax®23 makes
inter-laboratory comparisons diﬃcult
ELISA based technology is consistently used to measure response to ViCPS
Analytical discrepancies are evident between techniques used to determine antibody
concentrations to individual serotypes and when compared to the overall antibody
response to all Pneumovax®23 containing serotypes (Janssen et al., 2014; Reynolds
et al., 2015; Lopez et al., 2016; Dziadzio et al., 2017)
Consistency has been demonstrated between laboratory designed tests (LDT) and
commercially available ELISAs (Bausch-Jurken et al., 2017)
Development of normal reference ranges for a healthy population has proven diﬃcult in
the background of prevalent pneumococcal disease (Hare et al., 2009; Orange et al.,
2012; Bonilla et al., 2015)
Published normal reference ranges are available. Cut-oﬀs to identify responders and
non-responders have been identiﬁed (Ferry et al., 2004; Sánchez–Ramón et al., 2016;
Bausch-Jurken et al., 2017; Kumarage et al., 2017).
High baseline pneumococcal antibody concentrations are prevalent and aﬀects
interpretation of response to Pneumovax®23 (Hare et al., 2009)
Low baseline concentrations of Typhi Vi IgG antibodies has been demonstrated in
areas where disease prevalence is low and where it is endemic (Ferry et al., 2004;
Sánchez–Ramón et al., 2016; Kumarage et al., 2017)
Use of pneumococcal conjugate vaccines in immunisation and re-immunisation schedules
have made the interpretation of antibody response to Pneumovax23® potentially
challenging: misleadingly elevated responses to serotypes contained in conjugated
pneumococcal vaccines are evident in individuals who have previously received the
conjugated vaccine, masking a true polysaccharide response (Janssen et al., 2014;
Schaballie et al., 2016)
Limited availability of conjugated vaccines against typhoid fever makes interpretation
of antibody response to ViCPS less complicated (Szu, 2013; MacLennan et al., 2014;
Mitra et al., 2016; Jin et al., 2017)
Conjugated vaccines are only licensed in India and China and their use will be more
restricted than conjugated pneumococcal vaccines, especially in countries without
endemic typhoid fever (Szu, 2013; MacLennan et al., 2014; Mitra et al., 2016; Jin
et al., 2017).
Cross reactivity lower as Typhim Vi does not possess multiple serotypes
Lack of consensus on interpretation of response to Pneumovax®23 Interpretation not complicated by antibodies to multiple serotypes
Future availability of conjugated vaccines with increasing serotype coverage will render
interpretation and use even more challenging
Conjugated vaccines are only licensed in certain countries and its use will be more
restricted than conjugated pneumococcal vaccines (Szu, 2013; MacLennan et al.,
2014; Mitra et al., 2016; Jin et al., 2017).
High concentrations of pneumococcal IgG are present in antibody replacement products Typhi Vi IgG concentrations are low in antibody replacement products (Bausch-
Jurken et al., 2017)
A.R. Parker et al. Journal of Immunological Methods xxx (xxxx) xxx–xxx
2
The assessment of the IgG response to ViCPS is recommended
(Bonilla, 2018) but T cell independent type II antigens, such as ViCPS,
produce a predominately IgM antibody response. The measurement of
IgM response to polysaccharide vaccines has been suggested as addi-
tional tools to assess humoral immunity. Poor IgM responses to pneu-
mococcal antigens in patients with antibody deﬁciencies has been as-
sociated with increased risk of infections and co-morbidities, and may
have a particular utility in patients receiving IgG replacement therapy
(Cavaliere et al., 2012; Schutz et al., 2012; Echeverria de Carlos et al.,
2017). It can be envisaged that the IgM antibody response to poly-
saccharide ViCPS vaccinations may also have utility in assessing hu-
moral immunity, but to date there are no publications exploring this
avenue.
2.2. Baseline concentrations of Typhi Vi IgG antibodies
Independent studies have reported low baseline concentrations of
Typhi Vi IgG antibodies in children and adult blood donors (median
children 1.4 AU/mL, median adults 5.3 AU/mL, assay measuring range
of 0–95 AU/mL and median adult 8.6 U/mL, assay measuring range
7.4–600 U/mL) (Ferry et al., 2004; Sánchez–Ramón et al., 2016). The
percentage of individuals with baseline concentrations below assay
measuring ranges has been reported to be 40–71% (Fig. 1) (Parker
et al., 2014; Kumarage et al., 2017; Evans et al., 2018)) and age speciﬁc
adult baseline concentrations suggest peaks in concentration between
32–41 years and 72–81 years (Parker et al., 2014). Median baseline
Typhi Vi IgG concentrations are generally higher in adults compared to
children (Kim et al., 1995; Ferry et al., 2004; Parker and Harding, 2016;
Kumarage et al., 2017) and the range of concentrations wider
(7.4–300 U/mL vs. 7.4–39 U/mL assay measuring range 7.4–600 U/mL)
(Kumarage et al., 2017), however, conﬁrmation of this trend in larger
cohorts is required (Fig. 1). Global baseline Typhi Vi IgG concentrations
will likely remain relatively low since administration of the conjugate
vaccine will only be directed towards countries with endemic typhoid
fever and individuals travelling to them.
Some healthy individuals have been reported to have high pre-
vaccination concentrations, signiﬁcantly above the baseline con-
centrations ranges determined. Ferry et al. report 2/23 (Ferry et al.,
2004), Kumarage et al. report 2/24 (Kumarage et al., 2017) and Evans
et al. report 4/215 (Evans et al., 2018) healthy individuals with sig-
niﬁcantly higher baseline Typhi Vi concentrations, which may be in-
dicative of prior pathogen contact, previous vaccination or cross re-
activity with similar polysaccharide structures (Ferry et al., 2004).
Baseline concentrations have been suggested to be higher in areas of
endemic Typhoid fever (19% to 58% levels, > 1 μg/mL) in the absence
of vaccination (Klugman et al., 1996; Keddy et al., 1999; Panchanathan
et al., 2001; Staats et al., 2010). A direct comparison between the
baseline concentrations from an area with endemic typhoid fever to an
area without the fever, using the same commercial assay, provides some
support for this (median 8.6 (range 7.4–31.8) vs 10 (range 7.4–232))
(Sánchez–Ramón et al., 2016; Kumarage et al., 2017). As with antibody
responses to other vaccinations, high base-line concentrations of Typhi
Vi IgG antibodies could aﬀect the magnitude of response achieved
(Evans et al., 2018), however Kumarage et al. demonstrated that even
in an area endemic of typhoid fever> 95% of a control group had a
concentration below 100 U/mL suggesting that pre-vaccination con-
centrations may not be a limiting factor in the interpretation of re-
sponse to Typhi Vi vaccination.
2.3. Response to ViCPS vaccines in a control population
Several studies have identiﬁed fold increase cut-oﬀs in order to
deﬁne an adequate response to ViCPS in healthy control populations.
Using a one-sided 95% prediction interval, Schaballie and colleagues
demonstrated a 2-fold increase and 11.2 U/mL post-vaccination
Table 2
Commercially available vaccines licensed for use against Salmonella typhi.
Vaccine type Vaccine name Developer Licensed for use Reference
Live attenuated Ty21a (Vivotif®) Crucell Adults and Children>5 years (Ivanoﬀ et al., 1994; Pakkanen et al., 2015)
Vi Polysaccharide (ViCPS) Typhim Vi™ Sanoﬁ Pasteur Adults and Children ≥2 years (Acharya et al., 1987; Klugman et al., 1996; MacLennan et al.,
2014; World Health Organization, 2014; Schadich et al., 2016)Typherix™ GSK
Typbar® Bharat Biotech
Typho-Vi® Biomed
Vax-tyVi® Finlay Institute
Zerityph inj® Boryung
Typhevac inj® Shanghai Institute of
Biological Products
Vi-TT conjugate Peda-Typh™ Biomed Licensed in India (MacLennan et al., 2014) (Chinnasami et al., 2015) (Mitra et al.,
2016)
Typbar-TCV® Bharat Biotech Licensed in India (MacLennan et al., 2014) (Jin et al., 2017)
Vi-rEPA conjugate Vi-rEPA® Lanzhou Institute (China) Licensed in China (Szu, 2013; MacLennan et al., 2014)
Fig. 1. Baseline concentrations of Typhi Vi IgG are low in both healthy children
and adults.
Baseline Typhi Vi IgG concentrations in children and adult control groups. The
Typhi Vi pre-vaccination concentrations were determined in the two control
groups and separated into concentration ranges. The % individuals in the dif-
ferent concentration ranges were calculated. (A) Adult control group (n=24)
and (B) Children control group (n=20).
Measuring range of the assay is 7.4–600 U/mL.
Reprinted with permission (Kumarage et al., 2017).
A.R. Parker et al. Journal of Immunological Methods xxx (xxxx) xxx–xxx
3
concentration to deﬁne an adequate response to Typhim Vi® (Schaballie
et al., 2017). Bausch-Jurken and colleagues used receiver operator
characteristic (ROC) analysis to establish that a 1.95 fold-increase in
ViCPS antibodies resulted in an area under the curve of 1.00
(p < 0.0001) and thus proposed that a 2-fold increase cut-oﬀ accu-
rately discriminated between the control population and cohort of pa-
tients with known immunodeﬁciencies (Bausch-Jurken et al., 2017).
Several studies have deﬁned> 3-fold increases in antibody concentra-
tion post-vaccination as a normal response based on antibody con-
centration increases in> 94%,>95% and 100% of control groups
(Ferry et al., 2004; Sánchez–Ramón et al., 2016; Kumarage et al., 2017;
Evans et al., 2018). Sanchez-Ramon and colleagues also used ROC
analysis to demonstrate a 10 fold increase in antibody production to be
90.9% sensitive and 62.5% speciﬁc in the diﬀerentiation between
healthy controls and patients with CVID (Sánchez–Ramón et al., 2016).
Many studies have demonstrated highly immunogenic IgG re-
sponses to ViCPS vaccines in healthy control populations (Table 3). A
large clinical trial evaluating the immunogenicity of ViCPS vaccines in
Nepal, an area of endemic typhoid fever, reported 76.9%, 79.1% and
62.5% of individuals (aged 5-14 yrs., 15-44 yrs. and 45–55 years old,
respectively) achieved seroconversion, compared with a 95.5% ser-
oconversion rate in French and US individuals (Acharya et al., 1987).
More recently, two independent studies evaluated the response to
ViCPS vaccines using the same commercial assay (The Binding Site,
UK), allowing direct comparison between areas where the occurrence of
typhoid fever is low with an area where it is endemic. A higher post
vaccination concentration was reported where typhoid fever is endemic
(median 519 U/mL [95% CI 80–2779] (Kumarage et al., 2017) vs.
median 171 U/mL [range 32–600](Sánchez–Ramón et al., 2016)),
which may be consequential to slightly higher baseline concentrations
in areas where individuals may have prior exposure to the pathogen
and thus forms part of a secondary response.
In a study to determine predictors of response to ViCPS vaccines,
multivariate analysis revealed pre-vaccination concentration of ViCPS
antibodies to be a signiﬁcant predictor of antibody response (Moore
et al., 2012). Klugman et al. (1987) also demonstrated a greater
Table 3
Summary of post-vaccination ViCPS antibody concentrations and fold increases in healthy controls and primary antibody deﬁciency patients.
Healthy controls Antibody deﬁciency
Reference Units Post vaccination
concentration (95%
CI)
Fold increase in
concentration (95%
CI)
% obtaining ≥4fold
increase /seroconversion
rate
Post vaccination
concentration (95% CI)
Fold increase in
concentration (95% CI)
Children
(Kim et al., 1995) GMT 69.4 29†† 98.4
(Lim et al., 2007) GMT 142.6 24†† 96.9
(Miyazu et al., 2015) GMT 2–11 years
501.7 (305.3–824.5)
2–11 years
135.6 (82.5–222.8)
2–11 years
100
12-17 years
320 (230.6–444.2)
12–17 years
31.4 (9.2–107.9)
12–17 years
85.7
(Acharya et al., 1987) μg/mL 1.89 (0.4–8.9) 8 76.9
(Kumarage et al.,
2017)†
U/mL 679 (60–3029) 59 (7–236) 219 (12–815) 18 (1–56)
Adults
(Evans et al., 2018) U/mL 107 (31–542)‡ 100⁎ 23 (10–372)‡
(Sánchez–Ramón et al.,
2016)†
U/mL 171 (32–600)‡ 12.3 (3.4–76.9)‡ CVID
21 (7.4–277)‡
CVID
1.8 (1–37.4)‡
HYPOG
63.3 (7.4–600)‡
HYPOG
8.6 (1–81.1)‡
(Kumarage et al.,
2017)†
U/mL 519 (80–2779) 32 (5–135) 11 (7.4–1746) 2 (1–56)
(Kim et al., 1995) GMT 79.1 12†† 88.2
(Lim et al., 2007) GMT 58.7 10†† 89.0
(Acharya et al., 1987) μg/mL 15–44 years
3.7 (0.4–38.8)
15–44 years
10
15–44 years
79.1
45–55 years
4.4 (0.31–63.2)
45–55 years
8
45–55 years
62.5
(Keitel et al., 1994) μg/mL 3.2 16†† 93
(Klugman et al., 1987) ELISA OD 0.2 (0.1–0.3) 4††
(Bausch-Jurken et al.,
2017)
6.0 (2.1–16.8)‡ 100 ⁎⁎ 1.0 (0.8–1.8)‡
(Moore et al., 2012) ELISA U 7.2 (6.1–8.5) 13†† 63
(Miyazu et al., 2015) GMT 148.6 (126.9–174.0) 22.6 (19.1–26.8) 92
(Kroon et al., 1999) ††† AU/L 105.6 20 89 CD4+
>200×106/L
35.4
CD4+ > 200×106/L
29
CD4+ < 200×106/L
4.3
CD4+ < 200×106/L
4.4
Adults/children combined
(Schaballie et al., 2017) U/mL 71.5 15
HYPOG: Hypogammaglobulinaemia.
CI: Conﬁdence Interval.
⁎ % ≥3 fold increase.
⁎⁎ % ≥2 fold increase.
‡ Median concentration and range.
† Post vaccination concentrations have been obtained from the same commercial assay for comparison.
†† Fold increase results determined using vaccination data taken 1months post and pre vaccination.
††† Study compared response in two cohorts; those with<200×106/L CD4+ cells and those with> 200×106/L CD4+ cells.
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increase in Salmonella typhi Vi antibody titres one month post vacci-
nation in cohorts with lower pre-vaccination concentrations; a cohort
with pre-vaccination ELISA readings of< 0.1 OD elicited a 4.11 fold
increase, versus a 1.74 fold increase in those with a pre-vaccination
ELISA reading of> 0.1 OD (Klugman et al., 1987). Despite these re-
ports, in the context of a low prevalence of typhoid fever in developed
countries and the absence of routine use of conjugated vaccines, the
impact of pre-vaccination concentrations is unlikely to have as much
impact on the interpretation of response (Table 3).
Evaluation of immunotolerance to ViCPS vaccines is essential to
ensure interpretation of response is not hampered by pre-exposure to
ViCPS polysaccharide vaccines. Similar levels of antibody concentra-
tions against ViCPS antigens have been shown to be elicited after pri-
mary and booster vaccinations (Keitel et al., 1994). In a study com-
paring response to ViCPS vaccines in cohorts who had received multiple
vaccinations vs. a cohort who had not previously been vaccinated
against typhoid fever, there was no evidence of immunotolerance
(Roggelin et al., 2015). However, in a subsequent study a proportion of
the population of the study failed to produce plasmablasts speciﬁc to
ViCPS after a booster vaccination (Pakkanen et al., 2017) indicating
this is an area requiring further investigation.
The comparison between children and adult responses in a healthy
population has been demonstrated by Kumarage and colleagues; a
greater response was elicited in the paediatric group compared with the
adult group but it did not reach statistical signiﬁcance (post vaccina-
tion: median concentration (95% CI) (U/mL) children: 679 (60–3029)
versus adults: 519 (80–2779); median fold increase (95% CI, U/mL)
children: 59 (7–236) versus adults: 32 (5–135) (Kumarage et al., 2017).
Additionally, Kim and colleagues also report a higher seroconversion
rate in children compared with adults, 98.4% versus 88.2% one month
post vaccination (Kim et al., 1995). Data from paediatric populations is
of particular interest given the wide spread use of pneumococcal con-
jugate vaccines (PCV) in childhood vaccination schedules.
Given that infants are unable to mount polysaccharide-speciﬁc re-
sponses before the age of 2 years, SPAD can only be assessed after this
time point (Durandy et al., 2013). A diagnosis of a memory phenotype
of SPAD has been described, which is an adequate initial response to a
polysaccharide antigen that is not maintained at 6months post vacci-
nation (Orange et al., 2012). It is therefore essential that vaccines used
in the diagnosis of antibody deﬁciencies are able to induce responses in
healthy individuals that are relatively stable for at least a year post
vaccination. Studies have assessed the longevity of response to ViCPS
vaccines conﬁrming a stable response at 12months post-vaccination
and beyond (Table 4).
3. Utility of ViCPS vaccines as diagnostic tools for antibody
deﬁciency
3.1. Primary immunodeﬁciency
Response to ViCPS vaccines has been recommended for the assess-
ment of humoral immunity in individuals undergoing evaluation for
antibody deﬁciencies (Anonyms, 1999; Ferry et al., 2004; Orange et al.,
2012; De Silva et al., 2013) and could be of particular use in patients
who have been vaccinated with a conjugated pneumococcal vaccine.
Several studies have demonstrated the utility of measuring response to
ViCPS vaccines as an indicator of humoral immunity in patients with
primary antibody deﬁciencies, in diﬀerentiating responses in patients
with hypogammaglobulinaemia (HYPOG) and CVID from healthy
controls as well as stratifying PID patients who are at increased risk of
infection.
3.1.1. Response to ViCPS vaccines is restricted in patients with primary
antibody deﬁciencies
The IgG response to ViCPS vaccine may be defective in patients with
primary antibody deﬁciencies (Sánchez–Ramón et al., 2016; Bausch-
Jurken et al., 2017; Kumarage et al., 2017; Evans et al., 2018). Using a
laboratory developed test (LDT) ELISA, antibody response to Typhim
Vi® vaccination was determined in healthy controls, patients diagnosed
with primary antibody deﬁciencies and patients with possible humoral
immune deﬁciency (Bausch-Jurken et al., 2017). All patients diagnosed
with an antibody deﬁciency had an abnormal antibody response to
Typhim Vi®, as did seven patients with possible immunodeﬁciency that
were subsequently determined to have primary or secondary im-
munodeﬁciencies (Fig. 2). Kumarage and colleagues used a commer-
cially available ELISA assay to measure the antibody response to the
polysaccharide Typhi Vi vaccine, Typbar®, in patients referred for im-
munological evaluation in Sri Lanka, an area where typhoid fever is
endemic. In both paediatric and adult patients with primary antibody
deﬁciencies (CVID and HYPOG), antibody response to Typbar® vacci-
nation was lower than in the age-matched controls with 89% of pae-
diatric PID patients and 45% of adult PID patients obtaining a three-fold
increase in concentration post vaccination compared with 94% of the
control groups (median fold-increase [95% CI]: adult control group 32
(5–135) versus adult PID group 2 (1–56) and children control group 59
(7–236) versus children PID group 18 (1–56) (Kumarage et al., 2017)).
Evans and colleagues determined response to Typhim Vi® in 20 newly
diagnosed antibody deﬁcient patients; 40% did not respond to Typhim
Vi® (< 7.4 U/mL) and 30% achieved a > 3 fold increase (Evans et al.,
2018). The median post-vaccination concentrations were statistically
diﬀerent between this cohort and healthy volunteers (p=0.02).
3.1.2. Diﬀerentiation between healthy individuals and patients with
HYPOG and CVID
Two studies describe that the antibody response to ViCPS vaccina-
tion may diﬀerentiate between some CVID patients and HYPOG pa-
tients. Sánchez–Ramón and colleagues reported a multi-centre evalua-
tion of the use of Typhim Vi® in previously diagnosed PID patients
(Sánchez–Ramón et al., 2016). A ten-fold increase in Typhim Vi® an-
tibodies provided good discrimination between healthy individuals and
some patients with HYPOG and CVID (Fig. 3A) (Sánchez–Ramón et al.,
2016). Kumarage and colleagues also demonstrated that a three-fold
increase in Typhi Vi IgG diﬀerentiated between some CVID and HYPOG
patients and their corresponding controls groups (Kumarage et al.,
Table 4
Stability of ViCPS vaccine response up to 36months post-vaccination in healthy populations. Individuals were vaccinated with a single dose of 25 μg/0.5 mL ViCPS.
Reference Pre-vaccination Post-vaccination
1month 3months 6months 12months 36months
Sero-conversion (90%CI) Adult (Kim et al., 1995) 88.2 96.2 75.3 56.5
(Lim et al., 2007) 89.1 (83.3–94.7)
Children (Kim et al., 1995) 98.4 100 98.2 52.6
(Lim et al., 2007) 96.9 (93.4–100.4)
Geometric mean Titer (GMT) ± SD Adult (Kim et al., 1995) 6.6 79.1 120.3 41.7 28.3
(Lim et al., 2007) 5.7 ± 1.31 64.0 ± 2.81 105.0 ± 2.29 84.1 ± 2.12
Children (Kim et al., 1995) 2.4 69.4 49.2 36.7 7.2
(Lim et al., 2007) 6.0 ± 1.37 151.3 ± 2.28 110.0 ± 1.91 100.2 ± 1.67
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2017) (Fig. 3B). ROC curve analysis highlighted Typhim Vi® to be the
more sensitive assay in distinguishing between CVID and healthy con-
trols compared with Pneumovax®23 (AUC 0.893 versus 0.538)
(Sánchez–Ramón et al., 2016) (Fig. 3C). The failure to respond to ViCPS
vaccination has been used to aid diagnosis of antibody deﬁciencies,
particularly CVID (De Silva et al., 2013; Bausch-Jurken et al., 2017).
3.1.3. Stratiﬁcation of patients at risk of infection
Ferry and colleagues demonstrated an approximate 10-fold increase
between mean pre- and post-vaccination concentrations in 23 healthy
adults (geometric mean and 95% CI pre-vaccination 3.9 (2.4–6.5) and
post-Typhim Vi® vaccination 39.2 (24.8–61.3) (Ferry et al., 2004).
Sánchez–Ramón and colleagues proposed that diﬀerentiation of CVID
patients using a 10-fold increase cut-oﬀ may identify a subset of CVID
patients with a more proﬁcient humoral immunological response and
thus may possess lower risk of infection and possibly CVID associated
disorders. Supporting this, although not statistically signiﬁcant, they
reported two patients with a diagnosis of CVID with increased re-
sponses> 10-fold in concentration who had a lower number of re-
spiratory infections and none of the inﬂammatory conditions linked
with a diagnosis of CVID (Sánchez–Ramón et al., 2016).
3.2. Utility of measuring IgG antibodies in response to both Pneumovax®23
and ViCPS vaccines
Individuals may respond very diﬀerently to similar types of antigen
that vary in structure e.g. between diﬀerent pneumococcal serotypes
and between Pneumovax®23 and Typhim Vi®. Guidelines have sug-
gested measuring the response to two protein vaccines for the assess-
ment of antibody deﬁciency (Chapel and Cunningham-Rundles, 2009).
Currently, data analysing the response to two polysaccharides,
Fig. 2. Identiﬁcation of 7 patients with defective response to Typhim Vi®.
Speciﬁc antibody response to Typhim Vi® in healthy controls and patients with
known and possible immunodeﬁciencies (separated according to treatment
with IgG therapy). All patients with known immunodeﬁciency had abnormal
response to Typhim Vi®, as did 7/20 patients with possible immunodeﬁciency;
all were subsequently determined to have primary or secondary im-
munodeﬁciencies.
The dotted line indicates the pre-post-vaccination titer ratio≥ 2 (normal re-
sponse), solid lines indicate median and IQR. Ig indicates immunoglobulin re-
placement therapy at the time of vaccination. Statistical signiﬁcance indicated
as follows: ns not signiﬁcant, **p≤ 0.01.
Reprinted with permission (Bausch-Jurken et al., 2017).
(caption on next page)
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Pneumovax®23 and Typhim Vi®, are lacking.
Schaballie et al. identiﬁed 2/100 healthy individuals with abnormal
response to Pneumovax®23 and Typhim Vi® vaccines. Upon subsequent
investigation both had a history of repeated infections and the clinical
characteristics of one patient were suggestive of SPAD diagnosis. A
history indicative of immunodeﬁciency was not noted in any individual
who had a poor response to just one vaccine (Schaballie et al., 2017)
(Fig. 4).
In patients undergoing immunological evaluation, the responses to
Typhim Vi® and Pneumovax®23 can divide the patients into 4 groups.
Data from Sánchez-Ramón suggested that 13/45 (29%) HYPOG and
CVID patients did not have a similar response to both Typhim Vi® and
Pneumovax®23 (Fig. 5). Evans and colleagues demonstrated equivalent
responses to Typhim Vi and Pneumovax in 8/9 antibody deﬁcient pa-
tients (Evans et al., 2018). Further investigations will be of interest to
determine if stratiﬁcation of patients using both polysaccharide vac-
cines can identify patients at increased risk of infection. Moreover,
Ochoa-Grullón and colleagues investigated the response to Typhim Vi®
and Pneumovax®23 in 28 patients diagnosed with various haematolo-
gical malignancies (Ochoa-Grullón et al., 2017). 11/28 (39%) of all
patients did not have a similar response to both Typhim Vi® and
Pneumovax®23 (Fig. 6). Given that there is a high incidence of infection
among patients with haematological disorders and recipients of he-
matopoietic cell transplants (Blimark et al., 2015; Dhalla and Misbah,
2015) stratiﬁcation using both polysaccharide vaccines may be of
particular interest. Additional studies are needed to determine the
utility of measuring response to Typhi Vi polysaccharide vaccines to aid
identiﬁcation of patients with increased risk of infection.
3.3. Secondary immunodeﬁciency
B-cell lineage lymphoproliferative diseases such as chronic lym-
phocytic leukaemia and multiple myeloma (Dhalla and Misbah, 2015)
as well as treatment related immunosuppression such as with rituximab
or other biologicals can prevent antibody production resulting in severe
or prolonged HYPOG (Sánchez–Ramón et al., 2016).
Kroon and colleagues demonstrated that the response to Typhim Vi®
is compromised in individuals infected with the human im-
munodeﬁciency virus (HIV) (Kroon et al., 1999). Thirty HIV positive
individuals were vaccinated with Typhim Vi® and divided into 2
groups; those with greater than or< 200×106/L CD4+ T lympho-
cytes. In the group with>200×106/L CD4+ T lymphocytes, 86% of
individuals achieved a≥ 4 fold increase in concentration (mean fold
increase 29) compared to 89% in the healthy control group (mean fold
increase 20). The response was signiﬁcantly lower in those HIV patients
with< 200×106/L CD4+ T lymphocytes (25% achieving a≥ 4 FI,
mean 4.4).
Bausch-Jurken and colleagues reported the vaccination of 29 pa-
tients referred for immune system evaluation with the suspicion of PID
Fig. 3. Diﬀerentiation of HYPOG and CVID patients using measurement of
Typhim Vi® antibodies.
A) Reprinted with permission (Sánchez–Ramón et al., 2016).
Box plots showing that the Ratio Typhim Vi was signiﬁcantly higher in healthy
control-group (HC) compared to CVID-group (p < 0.0001), but not with re-
spect to HYPOG-group (p= 0.138). Each box plot represents the median (thick
band) and the 25th and 75th centiles. The error bars represent the smallest and
largest values that are not outliers.
B) Reprinted with permission (Kumarage et al., 2017).
Responses to Typhi Vi vaccination in control groups, HYPOG and CVID patients.
Typhi Vi responses were assessed in the children control group (n=20), adult
control group (n=24), HYPOG (n= 8) and CVID (n=8) groups. FI: fold in-
crease.
C) Reprinted with permission (Sánchez–Ramón et al., 2016).
Receiver operating characteristic (ROC) curve analyses using Typhim Vi and
PCP ratio as predictor of diagnosis of CVID. The curves show the trade-oﬀ be-
tween sensitivity and speciﬁcity. An increase in sensitivity will be accompanied
by a decrease in speciﬁcity. The accuracy of the prediction increases as the
curve approaches the left-hand and top portions of the ROC space. The area
under the curve (AUC) is the percentage of randomly drawn pairs for which the
prediction is true. As observed, the ratio Typhim Vi better deﬁned CVID pa-
tients (p < 0.0001). PCP: pneumococcal capsular polysaccharides.
Fig. 4. Failure to produce IgG antibodies in response
to Pneumovax®23 and/or Typhim Vi® in healthy
volunteers.
Venn diagram showing subjects (black dots) with
abnormal antibody response for each detection
method, among 100 healthy subjects (ﬁfth percentile
cut-oﬀ values were used). Subjects with normal test
results are not shown. Arrows indicate the clinical
history of two subjects with abnormal results for
both tests. URTI, upper respiratory tract infections.
Adapted from Schaballie et al. (2017).
Fig. 5. Combined measurement of IgG antibodies to Typhim Vi® and
Pneumovax®23 identiﬁes 4 groups of patients with immunodeﬁciency.
Speciﬁc antibody responses post-vaccination with Pneumovax®23 and Typhi
Vi® in healthy controls and patients diagnosed with PID. Dashed line (50mg/L)
represents lower end of normal response to Pneumovax®23 in health in-
dividuals (Chua et al., 2011); dotted line (32 U/mL) represents lowest response
to Typhim Vi® in healthy individuals (Sánchez–Ramón et al., 2016).
Data from Sánchez–Ramón
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(based largely on a history of recurrent upper respiratory tract infec-
tions) (Bausch-Jurken et al., 2017). Two patients were diagnosed with
secondary antibody deﬁciency: one with hemophagocytic lymphohis-
tiocytosis secondary to Epstein-Barr virus infection who was treated
with repeated doses of rituximab; and the other, HYPOG and T cell
lymphopenia secondary to non-Hodgkin's lymphoma treated with ri-
tuximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP). Both exhibited a < 2 fold increase in Typhim Vi® responses.
Furthermore, the response to Typhim Vi® was investigated in 28
patients diagnosed with various haematological malignancies (Ochoa-
Grullón et al., 2017). Only 5/28 achieved a post vaccination con-
centration of Typhim Vi antibodies> 32 U/mL and 5/28 achieved a
more that 3 fold increase (Sánchez–Ramón et al., 2016). All patients
with chronic lymphocytic leukaemia (n=5) and follicular lymphoma
(n=7) were non-responders (Fig. 6).
4. Measurement of Typhim Vi® IgG antibodies as tool for
monitoring patients with antibody deﬁciency
IGRT has been the mainstay for the management of primary and
secondary immunodeﬁciencies, particularly in those with a more severe
clinical phenotype (Orange et al., 2012; Jolles et al., 2017). Monitoring
of patients' total IgG concentrations is performed on regular basis by
measurement of the trough IgG levels and in particular situations, such
as SPAD, assessment of speciﬁc antibody levels may also be undertaken.
It has been proposed that for patients who are receiving IGRT, a
potential way to assess underlying endogenous vaccine responses is to
use immunisations not included in the standard vaccination schedules,
as baseline levels of these antibodies in immunoglobulin preparations
and endogenous levels would be expected to be low (Sobh and Bonilla,
2016; Jolles et al., 2017). Although several studies have reported a lack
of correlation between the measurement of total IgG and speciﬁc an-
tibody production, others have reported an adequate correlation
(Mikolajczyk et al., 2004; Chua et al., 2011; Adam and Church, 2015;
Jolles et al., 2017; Lee et al., 2017; Simao-Gurge et al., 2017).
The baseline concentration of Typhim Vi® antibodies in patients
receiving IGRT has been shown to be low (Bausch-Jurken et al., 2017;
Evans et al., 2018) and undetectable in four commercial preparations of
gammaglobulin (Gammagard®, Gamunex®–C, Subgam®, and Hizentra®)
(Bausch-Jurken et al., 2017) and so detection of ViCPS antibody re-
sponse in these patients is feasible.
Furthermore, Bausch-Jurken and colleagues reported the assess-
ment of the response to Typhim Vi® in 10 individuals with unknown
PID receiving IGRT. 7/10 had a≥ 2 fold-increase response and 3/10
a < 2 fold-increase (Fig. 2). Re-evaluation of these patients concluded
that the 7 responders were immunologically normal and IGRT was
discontinued (Bausch-Jurken et al., 2017). The suspected antibody
deﬁciencies in these individuals were due to untreated atopic disease
(e.g., allergic rhinitis, asthma). The 3/10 non-responders remained on
IGRT and were diagnosed with SPAD. The response to Typhim Vi® was
used as a key tool to aid the decision to cease treatment.
5. Conclusions
The response to ViCPS vaccines is of particular interest in the as-
sessment and risk stratiﬁcation of patients with suspected primary and
secondary immunodeﬁciency. Although measurement of antibodies
raised against Pneumovax®23 is the current gold standard test to assess
adaptive immunity to unconjugated T-cell independent polysaccharide
antigens, additional options, such as response to ViCPS vaccines, are
urgently needed to allow assessment where the utility of
Pneumovax®23 may be limited.
The use of ViCPS vaccine response in assessment of adaptive im-
munity has advantages (summarised in Table 1). The use of conjugate
vaccines is limited (Breukels et al., 1999; Janssen et al., 2014;
Schaballie et al., 2016) and generally baseline antibody concentrations
of Typhi Vi IgG are low, minimising memory B cell reactivation. Fur-
thermore, antibody concentrations have been reported in healthy con-
trol populations enabling assessment of response to ViCPS antibodies to
be relatively simple.
Current data suggests that combined measurement of antibodies to
Pneumovax®23 and Typhim Vi® may provide a wider window for ex-
ploration of the immune system (Sánchez–Ramón et al., 2016; Ochoa-
Grullón et al., 2017; Schaballie et al., 2017). This will be particularly
important for the growing group of patients with undeﬁned hypo-
gammaglobulinaemia who present with a broad range of disease se-
verity. The four groups for classifying non-responsiveness to poly-
saccharide antigens are currently based solely on the response to
Pneumovax®23 (Orange et al., 2012). An additional marker may pro-
vide further patient stratiﬁcation and standardisation of deﬁnitions as
well as aid in treatment decisions (Perez et al., 2017).
The utility of ViCPS has mainly been focused on diagnosis
(Sánchez–Ramón et al., 2016; Bausch-Jurken et al., 2017; Kumarage
et al., 2017) but it may also be informative in individuals receiving
IGRT (Bausch-Jurken et al., 2017).
In conclusion, the measurement of IgG antibodies raised in response
to typhoid polysaccharide vaccines has utility for the investigation of
adaptive immunity. This is likely to be an important addition to the
diagnostic toolkit for immunologists, used alongside Pneumovax®23, in
this complex and challenging area of immunological assessment.
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